PureTech Health Plcの資本の返還
PureTech Health Plcの資本の返還は何ですか。
PureTech Health Plcの資本の返還は-21.58%です。
資本の返還の定義は何ですか。
株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
LSEのセクタHealth Careにおける資本の返還の企業と比べるPureTech Health Plc
PureTech Health Plcは何をしますか。
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PureTech Health Plcと類似の資本の返還
- Harvest Goldの資本の返還は-21.61%です。
- Aura Resourcesの資本の返還は-21.61%です。
- First Light Capital Corpの資本の返還は-21.59%です。
- Great Southern Miningの資本の返還は-21.59%です。
- Rambler Metals and Mining PLCの資本の返還は-21.58%です。
- Rambler Metals and Mining PLCの資本の返還は-21.58%です。
- PureTech Health Plcの資本の返還は-21.58%です。
- KEFI Minerals Plcの資本の返還は-21.58%です。
- International Business Settlementの資本の返還は-21.56%です。
- Leading Edge Materialsの資本の返還は-21.53%です。
- Leading Edge Materialsの資本の返還は-21.53%です。
- Quantum Graphiteの資本の返還は-21.51%です。
- Magnis Technologiesの資本の返還は-21.50%です。